Potent, selective cdk2 inhibitor (IC50
values are 0.022, 0.04, 0.2, >10, >10, 18 and >100 μ
M for cdk2, cdk1, cdk4, PKC, p38, PDGFR and EGFR respectively). Inhibits pRb phosphorylation causing enhanced pRB/E2F complex formation and induces G1
-M cell cycle arrest. Transcriptionally downregulates Mcl-1 and has antiproliferative, cytostatic and pro-apoptotic effects in vitro
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
A novel cdk2-selective inhibitor, SU9516, induces apoptosis in colon carcinoma cells.
Lane et al.
Cancer Res., 2001;61:6170
SU9516, a cyclin-dependent kinase 2 inhibitor, promotes accumulation of high molecular weight E2F complexes in human colon carcinoma cells.
Yu et al.
The three-substituted indolinone cyclin-dependent kinase 2 inhibitor 3-[1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene]-5-methoxy-1,3-dihydro-indol-2-one (SU9516) kills human leukemia cells via down-regulation of Mcl-1 through a transcriptional m
Gao et al.
The citations listed below are publications that use Tocris products. Selected citations for SU 9516 include:
Showing Results 1 - 1 of 1